In this expert discussion Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) and Prof Kim Chi (Vancouver Prostate Centre, Vancouver, Canada) talk about the TITAN study and give updates on the latest data.
They also talk about what is next in terms of treatment for patients with hormone sensitive prostate cancer.
Initially, Prof Chi explains what the TITAN study was about and how it can effect the patients with hormone sensitive prostate cancer.
Prof Merseburger discusses androgen deprivation therapy and how it can lead to castration resistant prostate cancer and then they discuss other treatment options for such patients.
Prof Chi further discusses the efficacy of apalutamide and other treatment paradigms available for hormone sensitive prostate cancer patients like PARP inhibitors etc.
In the end, they discuss the future of hormone sensitive prostate cancer patients and what new treatments strategies can help them.
This programme has been supported by an unrestricted educational grant from Janssen.